BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 23011680)

  • 1. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
    van der Goes MC; Jacobs JW; Jurgens MS; Bakker MF; van der Veen MJ; van der Werf JH; Welsing PM; Bijlsma JW
    Osteoporos Int; 2013 Apr; 24(4):1429-36. PubMed ID: 23011680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss.
    Wijbrandts CA; Klaasen R; Dijkgraaf MG; Gerlag DM; van Eck-Smit BL; Tak PP
    Ann Rheum Dis; 2009 Mar; 68(3):373-6. PubMed ID: 18408246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
    Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
    Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis.
    Buckley LM; Leib ES; Cartularo KS; Vacek PM; Cooper SM
    J Rheumatol; 1997 Aug; 24(8):1489-94. PubMed ID: 9263140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of bisphosphonate might be important to improve bone mineral density in patients with rheumatoid arthritis even under tight control: the TOMORROW study.
    Tada M; Inui K; Sugioka Y; Mamoto K; Okano T; Anno S; Koike T
    Rheumatol Int; 2017 Jun; 37(6):999-1005. PubMed ID: 28405825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.
    Güler-Yüksel M; Allaart CF; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; van Groenendael JH; Mallée C; de Bois MH; Breedveld FC; Dijkmans BA; Lems WF
    Ann Rheum Dis; 2009 Mar; 68(3):330-6. PubMed ID: 18375540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial.
    Jensen TW; Hansen MS; Hørslev-Petersen K; Hyldstrup L; Abrahamsen B; Langdahl B; Zerahn B; Pødenphant J; Stengaard-Petersen K; Junker P; Østergaard M; Lottenburger T; Ellingsen T; Andersen LS; Hansen I; Skjødt H; Pedersen JK; Lauridsen UB; Svendsen AJ; Tarp U; Lindegaard H; Jurik AG; Vestergaard A; Hetland ML;
    Ann Rheum Dis; 2014 Jun; 73(6):1123-9. PubMed ID: 23661492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.
    Dore RK; Cohen SB; Lane NE; Palmer W; Shergy W; Zhou L; Wang H; Tsuji W; Newmark R;
    Ann Rheum Dis; 2010 May; 69(5):872-5. PubMed ID: 19734132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures?
    van Everdingen AA; Siewertsz van Reesema DR; Jacobs JW; Bijlsma JW
    Clin Exp Rheumatol; 2003; 21(2):155-60. PubMed ID: 12747268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial.
    Mok CC; Ying KY; To CH; Ho LY; Yu KL; Lee HK; Ma KM
    Ann Rheum Dis; 2011 May; 70(5):778-84. PubMed ID: 21187295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The limited effects of anti-tumor necrosis factor blockade on bone health in patients with rheumatoid arthritis under the use of glucocorticoid.
    Okano T; Koike T; Tada M; Sugioka Y; Mamoto K; Wakitani S; Nakamura H
    J Bone Miner Metab; 2014 Sep; 32(5):593-600. PubMed ID: 24233123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
    Güler-Yüksel M; Bijsterbosch J; Goekoop-Ruiterman YP; de Vries-Bouwstra JK; Hulsmans HM; de Beus WM; Han KH; Breedveld FC; Dijkmans BA; Allaart CF; Lems WF
    Ann Rheum Dis; 2008 Jun; 67(6):823-8. PubMed ID: 17644545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids.
    Habib GS; Haj S
    Clin Rheumatol; 2005 Apr; 24(2):129-33. PubMed ID: 15372317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Emkey R; Delmas PD; Goemaere S; Liberman UA; Poubelle PE; Daifotis AG; Verbruggen N; Lombardi A; Czachur M
    Arthritis Rheum; 2003 Apr; 48(4):1102-8. PubMed ID: 12687554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
    Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
    Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC; Tong KH; To CH; Siu YP; Ma KM
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis of tumor necrosis factor inhibitors and glucocorticoids on bone density in rheumatoid arthritis and ankylosing spondylitis trials.
    Siu S; Haraoui B; Bissonnette R; Bessette L; Roubille C; Richer V; Starnino T; McCourt C; McFarlane A; Fleming P; Kraft J; Lynde C; Gulliver W; Keeling S; Dutz J; Pope JE
    Arthritis Care Res (Hoboken); 2015 May; 67(6):754-64. PubMed ID: 25418272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
    Saag KG; Pannacciulli N; Geusens P; Adachi JD; Messina OD; Morales-Torres J; Emkey R; Butler PW; Yin X; Lems WF
    Arthritis Rheumatol; 2019 Jul; 71(7):1174-1184. PubMed ID: 30816640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.